Document and Entity Information
Document and Entity Information | 6 Months Ended |
Jun. 30, 2022 shares | |
Cover [Abstract] | |
Document Type | 10-Q |
Amendment Flag | false |
Document Quarterly Report | true |
Document Period End Date | Jun. 30, 2022 |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Year Focus | 2022 |
Document Fiscal Period Focus | Q2 |
Document Transition Report | false |
Entity File Number | 0-15586 |
Entity Registrant Name | U.S. NeuroSurgical Holdings, Inc. |
Entity Central Index Key | 0001089815 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 47-5370333 |
Entity Address, Address Line One | 2400 Research Blvd, Suite 325 |
Entity Address, City or Town | Rockville |
Entity Address, State or Province | MD |
Entity Address, Postal Zip Code | 20850 |
City Area Code | 301 |
Local Phone Number | 208-8998 |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 7,792,185 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 1,096,000 | $ 2,178,000 |
Other current assets | 57,000 | 65,000 |
Total current assets | 1,153,000 | 2,243,000 |
Other assets: | ||
Due from related parties | 1,000 | 930,000 |
Investments in unconsolidated entities | 150,000 | 141,000 |
Goodwill | 315,000 | 315,000 |
Total other assets | 466,000 | 1,386,000 |
Property and equipment: | ||
Operating lease right-of-use asset | 40,000 | 59,000 |
Total property and equipment | 40,000 | 59,000 |
TOTAL ASSETS | 1,659,000 | 3,688,000 |
Current liabilities: | ||
Operating lease right-of-use liability - current portion | 45,000 | 43,000 |
Accounts payable and accrued expenses | 83,000 | 169,000 |
Due to related parties | 47,000 | 0 |
Income taxes payable | 231,000 | 414,000 |
Total current liabilities | 406,000 | 626,000 |
Operating lease right-of-use liability - net of current portion | 0 | 23,000 |
Guarantee liability | 11,000 | 11,000 |
Total liabilities | 417,000 | 660,000 |
EQUITY | ||
Common stock - par value $.01; 25,000,000 shares authorized; 7,792,185 shares issued and outstanding at June 30, 2022 and December 31, 2021 | 78,000 | 78,000 |
Additional paid-in capital | 2,871,000 | 2,871,000 |
Accumulated deficit | (1,891,000) | (373,000) |
U.S. Neurosurgical Holdings, Inc. stockholders' equity | 1,058,000 | 2,576,000 |
Noncontrolling interests | 184,000 | 452,000 |
Total equity | 1,242,000 | 3,028,000 |
TOTAL LIABILITIES AND EQUITY | $ 1,659,000 | $ 3,688,000 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Jun. 30, 2022 | Dec. 31, 2021 |
STOCKHOLDERS' EQUITY | ||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 25,000,000 | 25,000,000 |
Common stock, shares issued (in shares) | 7,792,185 | 7,792,185 |
Common stock, shares outstanding (in shares) | 7,792,185 | 7,792,185 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] | ||||
Revenue | $ 0 | $ 0 | $ 0 | $ 1,061,000 |
Costs and expenses: | ||||
Patient expenses | 0 | 86,000 | ||
Selling, general and administrative | 292,000 | 249,000 | 652,000 | 547,000 |
Total | 292,000 | 249,000 | 652,000 | 633,000 |
Operating (loss) income | (292,000) | (249,000) | (652,000) | 428,000 |
Total other (expense) income | ||||
Interest expense | 0 | (1,000) | 0 | (3,000) |
Interest income - sales-type sublease | 0 | 8,000 | ||
Loss from investments in unconsolidated entities, net | (998,000) | (135,000) | (1,131,000) | (274,000) |
Total other expense | (998,000) | (136,000) | (1,131,000) | (269,000) |
(Loss) income before income taxes | (1,290,000) | (385,000) | (1,783,000) | 159,000 |
Provision for income taxes | 1,000 | 232,000 | 3,000 | 484,000 |
Net loss | (1,291,000) | (617,000) | (1,786,000) | (325,000) |
Net loss attributable to noncontrolling interests | 194,000 | 0 | 268,000 | 0 |
Net loss attributable to U.S. Neurosurgical Holdings, Inc. | $ (1,097,000) | $ (617,000) | $ (1,518,000) | $ (325,000) |
Basic net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share) | $ (0.14) | $ (0.08) | $ (0.19) | $ (0.04) |
Diluted net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share) | $ (0.14) | $ (0.08) | $ (0.19) | $ (0.04) |
Weighted average common shares outstanding, basic (in shares) | 7,792,185 | 7,792,185 | 7,792,185 | 7,792,185 |
Weighted average common shares outstanding, diluted (in shares) | 7,792,185 | 7,792,185 | 7,792,185 | 7,792,185 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (1,786,000) | $ (325,000) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||
Amortization of operating lease right-of-use asset | 19,000 | 17,000 |
Loss from investments in unconsolidated entities, net | 1,131,000 | 274,000 |
Distributed earnings from unconsolidated entities | 11,000 | 0 |
Changes in: | ||
Accounts receivable | 0 | 346,000 |
Income taxes receivable/payable | (183,000) | 369,000 |
Other current assets | 8,000 | 10,000 |
Accounts payable and accrued expenses | (86,000) | (36,000) |
Operating lease right-of-use liability | (21,000) | (20,000) |
Net cash (used in) provided by operating activities | (907,000) | 635,000 |
Cash flows from investing activities: | ||
Advances to unconsolidated entities | (175,000) | (288,000) |
Principal payments received under sales-type sublease | 0 | 532,000 |
Net cash (used in) provided by investing activities | (175,000) | 244,000 |
Cash flows from financing activities: | ||
Repayment of finance lease obligations | 0 | (89,000) |
Net cash used in financing activities | 0 | (89,000) |
Net change in cash and cash equivalents | (1,082,000) | 790,000 |
Cash and cash equivalents - beginning of period | 2,178,000 | 2,030,000 |
Cash and cash equivalents - end of period | 1,096,000 | 2,820,000 |
Cash paid for: | ||
Interest | 0 | 3,000 |
Income taxes | $ 183,000 | $ 158,000 |
Basis of Preparation
Basis of Preparation | 6 Months Ended |
Jun. 30, 2022 | |
Basis of Preparation [Abstract] | |
Basis of Preparation | Note A - Basis of Preparation The accompanying Condensed Consolidated Financial Statements of U.S. NeuroSurgical Holdings, Inc. and Subsidiaries (the “Company”) as of June 30, 2022, and 2021, are unaudited. However, in the opinion of management, such statements include all adjustments necessary for a fair statement of the information presented therein. The Consolidated Balance Sheet at December 31, 2021, has been derived from the audited Consolidated Financial Statements at that date appearing in the Company’s Annual Report on Form 10-K/A. Pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying Condensed Consolidated Financial Statements and notes do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Accordingly, these statements should be read in conjunction with the Company’s most recent annual Consolidated Financial Statements. Consolidated results of operations for interim periods are not necessarily indicative of those to be achieved for full fiscal years. The only change to the Company’s equity in the three and six months ended June 30, 2022, and 2021 was net loss for the periods. The Company applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, The Company recognizes revenue in accordance with two different accounting standards: 1) Topic 606 and 2) Accounting Standards Codification (“ASC”) Topic 842, Leases The Company primarily generated revenue, in 2021, from a leasing arrangement with New York University, which is not within the scope of Revenue from Contracts with Customers The tables below present financial information associated with our leases. Classification June 30 June 30 Assets Long-term Operating lease assets Operating lease right-of-use asset $ 40,000 $ 77,000 Total leased assets $ 40,000 $ 77,000 Liabilities Current Operating lease liabilities Operating lease right-of-use liability - current portion $ 45,000 $ 41,000 Long-term Operating lease liabilities Operating lease right-of-use liability - net of current portion $ - $ 45,000 Total lease liabilities $ 45,000 $ 86,000 Lease Cost Operating lease cost Selling, general and administrative $ 21,000 $ 20,000 Finance lease cost Interest on lease liabilities Interest expense - 2,000 Sublease income Interest income - sales-type sublease - 8,000 Net lease expense $ 21,000 $ 14,000 Maturity of lease liabilities (as of June 30 2022 Operating lease 2022 $ 23,000 2023 24,000 Total 47,000 Less amount representing interest 2,000 Present value of lease liabilities $ 45,000 Discount rate 5.850 % |
Gamma Knife at NYU Medical Cent
Gamma Knife at NYU Medical Center | 6 Months Ended |
Jun. 30, 2022 | |
Gamma Knife at NYU Medical Center [Abstract] | |
Gamma Knife at NYU Medical Center | Note B – Gamma Knife at NYU Medical Center U.S. NeuroSurgical, Inc. (“USN”), a wholly-owned subsidiary of U.S. NeuroSurgical Holdings, Inc. , opened a New York gamma knife treatment center in July 1997 on the campus of New York University (“NYU”) Medical Center. The Company’s contract with NYU, its only customer, ended in March 2021. Upon termination of the NYU contract, the Company recognized a gain of $100,000 relating to previously accrued expenses. This gain was included as a reduction in selling, general and administrative expense in the quarter ended March 31, 2021. The Company is actively seeking new business ventures and believes that its cash reserves, which are in excess of $1.0 million at June 30, 2022, will allow the Company the opportunity do so. Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations. In addition to these activities, the Company has been exploring possible combinations with other existing businesses that would create a larger operating entity that would better justify the expenses involved in continuing as an independent publicly traded company. |
The Southern California Regiona
The Southern California Regional Gamma Knife Center | 6 Months Ended |
Jun. 30, 2022 | |
The Southern California Regional Gamma Knife Center [Abstract] | |
The Southern California Regional Gamma Knife Center | Note C – The Southern California Regional Gamma Knife Center During 2007, the Company, through a noncontrolling interest in joint ventures, managed the formation of the Southern California Regional Gamma Knife Center at San Antonio Regional Hospital (“SARH”) in Upland, California. Corona Gamma Knife, LLC (“CGK”) is party to a 14-year agreement with SARH to renovate space in the hospital and install and operate a Leksell PERFEXION gamma knife. CGK leases the gamma knife from NeuroPartners LLC, which holds the gamma knife equipment. In addition to returns on its ownership interests, USN Corona, Inc., (“USNC”), a wholly-owned subsidiary of USNH, expects to receive fees for management services relating to the facility. USNC is a 20% owner of NeuroPartners LLC and owns 39% of CGK. USNC was a 20% guarantor on NeuroPartners LLC’s seven-year lease with respect to the gamma knife equipment and certain leasehold improvements at SARH. In February 2016, NeuroPartners LLC negotiated a new five-year lease to fund the reloading of cobalt and related construction services. The new lease of $1,663,000 included a balance of $668,000 from the prior lease obligations. This new lease was payable over 60 months. The first payment of $31,000 was paid in April 2016 and the final payment was paid in March 2021, removing USNC’s guarantee obligation. Construction of the SARH gamma knife center was completed in December 2008 and the first patient was treated in January 2009, at which time the 14-year gamma knife lease with SARH commenced. The project has been funded principally by outside investors. While the Company, through its joint ventures, has led the effort in organizing the business and overseeing the development and operation of the SARH center, its investment to date in the SARH center has been minimal. At June 30, 2022 and December 31, 2021, the Company’s recorded investment (loss) of NeuroPartners LLC and CGK was $0 and ($10,000), respectively. For the six months ended June 30, 2022, the Company’s equity in loss of NeuroPartners LLC and CGK was $28,000 compared to $7,000 for the six months ended June 30, 2021. At June 30, 2022, amounts due to related parties was $47,000 compared with $6,000 due from related parties at December 31, 2021. The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK: NeuroPartners LLC and CGK Condensed Combined Income Statement Information Six Months Ended June 30, 2022 2021 Patient Revenue $ 277,000 $ 336,000 Net (loss) income $ (27,000 ) $ 27,000 USNC’s equity in loss of NeuroPartners, LLC and CGK $ (28,000 ) $ (7,000 ) Three Months Ended June 30, 2022 2021 Patient revenue $ 155,000 $ 170,000 Net income $ 3,000 $ 8,000 USNC’s equity in loss of NeuroPartners LLC and CGK $ (38,000 ) $ (5,000 ) NeuroPartners LLC and CGK Condensed Combined Balance Sheet Information June 30, 2022 December 31, 2021 Current assets $ 370,000 $ 299,000 Noncurrent assets 166,000 294,000 Total assets $ 536,000 $ 593,000 Current liabilities $ 535,000 $ 564,000 Noncurrent liabilities - - Equity 1,000 29,000 Total liabilities and equity $ 536,000 $ 593,000 |
Florida Oncology Partners
Florida Oncology Partners | 6 Months Ended |
Jun. 30, 2022 | |
Florida Oncology Partners [Abstract] | |
Florida Oncology Partners | Note D – Florida Oncology Partners During 2010, through the formation of a joint venture, in which it had a noncontrolling interest, the Company expanded its market strategy to include opportunities to develop cancer centers featuring radiation therapy. In 2010, the Company formed FOP in partnership with local physicians and other investors. USNC owned a 24% interest in the venture. FOP abandoned its operations on June due to continued losses at the site of operations and lack of success in good faith efforts to renegotiate an agreement with the party from whom FOP leased a facility and equipment, after several months of discussion. Due to the circumstances, FOP derecognized the associated assets and liabilities and calculated a contingent liability equal to the net liabilities derecognized. On November the lessor filed a Voluntary Motion to Dismiss its lawsuit against FOP, and on December it was accepted and recorded by the court. There can be no guarantee the lessor will not reinstitute any future claims against FOP . The Company’s recorded investment in FOP prior to dissolution had been reduced to zero due to losses incurred in prior years. No equity in earnings had been recorded by the Company due to FOP’s deficit equity. On September 21, 2021, FOP filed Articles of Dissolution with the Florida Department of State that were recorded on September 22, 2021. FOP is now fully dissolved. |
Boca Oncology Partners
Boca Oncology Partners | 6 Months Ended |
Jun. 30, 2022 | |
Boca Oncology Partners [Abstract] | |
Boca Oncology Partners | Note E – Boca Oncology Partners During the quarter ended June 30, 2011, the Company, through the formation of a joint venture, in which it had a noncontrolling interest, participated in the formation of Boca Oncology Partners, LLC (“BOP”), for the purpose of owning and operating a cancer center in Boca Raton, Florida. In June 2011, Boca Oncology Partners RE, LLC (“BOPRE”,) an affiliated entity, purchased a 20% interest in Boca West IMP, owner of a medical office building in West Boca, Florida in which BOP operates. BOP occupies 6,000 square feet of the 32,000 square foot building. The Company invested $225,000 initially and had a 22.5% interest in BOP and BOPRE. In February 2014, the Company and other members sold their interests in BOP. In June 2012, BOPRE purchased an additional 3.75% of Boca West IMP from another investor bringing its total interest to 23.75%. BOPRE accounts for this investment under the cost method since it does not exercise significant influence over Boca West, IMP. During the years ended December 31, 2018, and 2017, several investors relinquished part of their ownership interest in BOPRE, and those interests were distributed among the remaining investors in relationship to their percentages owned. During 2021 and 2022, additional members relinquished their ownership to USNC. As a result, the Company now holds a 24.36% ownership interest in BOPRE, which it accounts for under the equity method. The Company’s recorded investment in BOPRE is $150,000 and $151,000 at June 30, 2022 and December 31, 2021, respectively. The following tables present the summarized financial information of BOPRE: BOPRE Condensed Income Statement Information Six Months Ended June 30, 2022 2021 Rental Income $ - $ - Net income $ 31,000 $ 56,000 USNC’s equity in earnings of BOPRE $ 8,000 $ 12,000 Three Months Ended June 30, 2022 2021 Rental Income $ - $ - Net income $ 14,000 $ 38,000 USNC’s equity in earnings of BOPRE $ 4,000 $ 9,000 BOPRE Condensed Balance Sheet Information June 30, 2022 December 31, 2021 Current assets $ 94,000 $ 112,000 Noncurrent assets 757,000 757,000 Total assets $ 851,000 $ 869,000 Current liabilities $ - $ - Noncurrent liabilities - - Equity 851,000 869,000 Total liabilities and equity $ 851,000 $ 869,000 |
Medical Oncology Partners
Medical Oncology Partners | 6 Months Ended |
Jun. 30, 2022 | |
Medical Oncology Partners [Abstract] | |
Medical Oncology Partners | Note F - Medical Oncology Partners In April 2015, Medical Oncology Partners, LLC (“MOP”), was formed in partnership with local physicians and other investors. MOP was established to acquire a 100% equity interest in United Oncology Medical Associates of Florida, LLC, (“UOMA”). USNC was not a member of MOP at the time of formation as it was not able to participate due to the fact that USNC was not a physician. Nevertheless, USNC wished to eventually obtain an equity interest in MOP and loaned Dr. Jaime Lozano, the principal investor in MOP and a co-investor in FOP, $173,000. Dr. Lozano used these funds, along with an equal amount of his own funds (a total of $345,000), to purchase a 76.67% interest in MOP. Other investors paid a further $105,000 for the remaining equity in MOP. MOP used the $450,000 of financing to acquire a 100% equity interest in UOMA. An application was filed for a waiver to allow USNC to hold an equity interest notwithstanding the physician requirement and on December 22, 2016, USNC was cleared to become a part owner of MOP. Dr. Lozano agreed to exchange half of his membership interest to USNC in settlement of the note to USNC. USNC and Dr. Lozano also agreed to share equally in providing a 5% equity interest in MOP to an additional investor as a consulting fee for services rendered in the administration of MOP and UOMA. At December 22, 2016, USNC owned 35.83% of MOP with an initial carrying value of $161,000. The Company recorded its share of losses of $12,000 for the period from December 22, 2016, to December 31, 2016, against its investment which resulted in a reduction of its equity investment to $149,000. Due to increasing costs, continued net losses since April 2015, and reliance on related party and other debt for operating cash flows, the fair value of UOMA is less than its carrying amount. The Company tested its investment for impairment at December 31, 2016 and determined that the investment was impaired, and an impairment loss was recorded against the entire equity balance in MOP, as well as loans from USN and USNC to MOP and UOMA. For the six months ended June 30, 2022, and 2021, the Company’s equity in loss of MOP was $92,000 and $34,000, respectively, but was not recorded due to prior losses. During the six months ended June 30, 2022, and 2021, the Company advanced $189,000 and $277,000, all of which has been fully impaired. These allowances and write offs were recorded as losses from investments in unconsolidated entities. Due to loans made to MOP and UOMA, MOP and UOMA are considered to be variable interest entities of the Company. However, as the Company is not deemed to be the primary beneficiary of MOP or UOMA, since it does not have the power to direct the operating activities that most significantly affect MOP’s or UOMA’s economic performance, the entities are not consolidated, but certain disclosures are provided herein. The following table presents the summarized financial information of MOP: MOP Condensed Consolidated Income Statement Information Six Months Ended June 30, 2022 2021 Patient revenue $ 1,067,000 $ 1,068,000 Net loss $ (256,000 ) $ (95,000 ) USNC’s equity in loss in MOP $ (92,000 ) $ (34,000 ) Three Months Ended June 30, 2022 2021 Patient revenue $ 534,000 $ 531,000 Net loss $ (68,000 ) $ 73,000 USNC’s equity in loss of MOP $ (53,000 ) $ 26,000 MOP Condensed Consolidated Balance Sheet Information June 30, 2022 December 31, 2021 Current assets $ 284,000 $ 201,000 Noncurrent assets 241,000 384,000 Total assets $ 525,000 $ 585,000 Current liabilities $ 3,326,000 $ 3,109,000 Noncurrent liabilities 64,000 92,000 Deficit (2,865,000 ) (2,616,000 ) Total liabilities and deficit $ 525,000 $ 585,000 |
CB Oncology Partners
CB Oncology Partners | 6 Months Ended |
Jun. 30, 2022 | |
CB Oncology Partners [Abstract] | |
CB Oncology Partners | Note G - CB Oncology Partners CBOP was organized September 1, 2017, to acquire the rights of a new cancer treatment center from FOP. USNC originally had a 24% equity interest in CBOP. Beginning in October of 2017, CBOP began paying the remainder of the costs associated with opening the center. The medical center opened and treated its first patient in January of 2018. Effective November 15, 2019, FOP transferred to, and CBOP assumed, a loan with BB&T bank, that it had entered into in order to finance the purchase of equipment and build out of the new center, as well as the associated property and equipment. In addition, CBOP and BB&T agreed to reduce the monthly loan repayments for the next nine months, and to extend the term of the loan from November 2024 to July 2025. In July 2020 CBOP and BB&T further agreed to reduce the monthly payments for the life of the loan and extended the loan to July of 2027. In June 2020, CBOP made a $500,000 capital call to its members. UNSC converted previously-made advances totaling $121,000 into equity in CBOP to meet its capital requirement, and other members contributed $212,000 in cash. The remaining capital contributions are not expected to be met and, accordingly, the Company’s equity interest in CBOP increased to 28.58% in June 2020. Amounts due from CBOP at June 30, 2022, totaled $2,211,000 of which all of it has been reserved against as of June 30,2022. These balances accrued interest at 6% per annum. Total accrued interest was $427,000 at June 30, 2022, and $335,000 at June 30, 2021, all of which has been fully reserved for. The Company records increases in the allowance as a component of loss from investments in unconsolidated entities and as a deduction in interest income for interest earned. Due to loans made to CBOP, CBOP is considered to be a variable interest entity of the Company. However, as the Company is not deemed to be the primary beneficiary of CBOP, since it does not have the power to direct the operating activities that most significantly affect CBOP’s economic performance, the entity is not consolidated, but certain disclosures are provided herein. The following table presents the summarized financial information of CBOP: CBOP Condensed Income Statement Information Six Months Ended June 30, 2022 2021 Patient revenue $ 1,026,000 $ 1,041,000 Net (loss) income $ (237,000 ) $ 92,000 USNC’s equity in (loss) income of CBOP $ (68,000 ) $ 26,000 Three Months Ended June 30, 2022 2021 Patient revenue $ 444,000 $ 570,000 Net (loss) income $ (191,000 ) $ 30,000 USNC’s equity in (loss) income of CBOP $ (55,000 ) $ 8,000 CBOP Condensed Balance Sheet Information June 30, 2022 December 31, 2021 Current assets $ 526,000 $ 400,000 Noncurrent assets 3,362,000 3,667,000 Total assets $ 3,888,000 $ 4,067,000 Current liabilities $ 3,826,000 $ 3,472,000 Noncurrent liabilities 2,826,000 3,121,000 Deficit (2,764,000 ) (2,526,000 ) Total liabilities and deficit $ 3,888,000 $ 4,067,000 |
Elite Health
Elite Health | 6 Months Ended |
Jun. 30, 2022 | |
Elite Health [Abstract] | |
Elite Health | Note H – Elite Health Effective October 1, 2021, U.S. NeuroSurgical, Inc. (“USN”), acquired all of the outstanding shares of capital stock of Elite Health Plan, Inc., a California corporation (“Elite Health”.) The transaction with Elite Health was structured as an investment by Elite Health shareholders in USN, and as such did not have an immediate effect on the percentage ownership of the shareholders of the Company. However, the Company’s interest in USN, which currently holds substantially all of the interest in the Company’s businesses and operations, was effectively diluted by 15% as a result of the issuance of the new USN shares to the former shareholders of Elite Health. Elite Health is a private company with a limited operating history. It was formed in 2017 with the purpose of establishing a managed care organization that will operate as a Medicare Advantage plan for seniors. It is expected that Elite Health will operate in California, initially San Bernardino, Riverside, and Orange Counties, with the objective of addressing the growing number of Medicare eligible seniors in those markets. Elite Health is in the process of applying for a Knox Keene license to operate a Medicare Advantage plan in California and has taken preliminary steps toward identifying a network of providers who are well-versed in the healthcare needs of seniors in the communities in which they practice. If Elite Health is successful in obtaining the license, establishing Elite Health as an operating entity will require significant investment not currently available to the Company. The Company is currently exploring opportunities to provide the necessary funding to proceed with activities required to launch Elite Health. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2022 | |
Income Taxes [Abstract] | |
Income Taxes | Note I – Income Taxes The Company’s income tax rate, which includes federal and state income taxes, was approximately 0% and 304%, for the six months ended June 30, 2022, and 2021, respectively. The Company recorded a tax charge of $3,000 and $484,000 for the six months ended June 30, 2022, and 2021, respectively. |
Restatement of Previously Issue
Restatement of Previously Issued Financial Statements | 6 Months Ended |
Jun. 30, 2022 | |
Restatement of Previously Issued Financial Statements [Abstract] | |
Restatement of Previously Issued Financial Statements | Note J - Restatement of Previously Issued Financial Statements During the quarter ended March 31, 2022, the Company determined that in March 2021, pursuant to an agreement with New York University ("NYU"), ownership of all of the gamma knife equipment at the NYU Medical Center transferred from the Company to NYU, resulting in the recognition of a gain on the sale and transfer of the gamma knife property on the Company's December 31, 2021 income tax returns. The Company previously received insurance proceeds with the Gamma Knife facility, which was destroyed as a result of flooding from Hurricane Sandy. For tax purposes, the resulting gain becomes taxable when the replacement property is sold or disposed of, which occurred in 2021. As a result, the Company recorded this tax liability and restated its consolidated financial statements as of and for the year ended December 31, 2021 and each of the quarters during the year ended December 31, 2021 on Form 10-K/A for the year ended December 31, 2021. The restatement tables below present a reconciliation from the previously reported to the restated values as of and for the three and six months ended June 30, 2021. The values as previously reported were derived from the Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 filed on August 11, 2021. CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS For the Three Months Ended June 30, 2021 As previously Restatement Reported Impacts As Restated Income tax provision $ 189,000 $ 43,000 $ 232,000 Net loss $ (574,000 ) $ (43,000 ) $ (617,000 ) Basic and diluted net loss per share $ 0.07 $ (0.01 ) $ (0.08 ) CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS For the Six Months Ended June 30, 2021 Income tax provision $ 194,000 $ 290,000 $ 484,000 Net loss $ (35,000 ) $ (290,000 ) $ (325,000 ) Basic and diluted net loss per share $ (0.00 ) $ (0.04 ) $ (0.04 ) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Six Months Ended June 30, 2021 Net loss $ (35,000 ) $ (290,000 ) $ (325,000 ) Change in: Income taxes receivable/payable $ - $ 369,000 $ 369,000 Deferred income taxes $ 79,000 $ (79,000 ) $ - |
Basis of Preparation (Tables)
Basis of Preparation (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Basis of Preparation [Abstract] | |
Financial Information Associated with our Leases | The tables below present financial information associated with our leases. Classification June 30 June 30 Assets Long-term Operating lease assets Operating lease right-of-use asset $ 40,000 $ 77,000 Total leased assets $ 40,000 $ 77,000 Liabilities Current Operating lease liabilities Operating lease right-of-use liability - current portion $ 45,000 $ 41,000 Long-term Operating lease liabilities Operating lease right-of-use liability - net of current portion $ - $ 45,000 Total lease liabilities $ 45,000 $ 86,000 Lease Cost Operating lease cost Selling, general and administrative $ 21,000 $ 20,000 Finance lease cost Interest on lease liabilities Interest expense - 2,000 Sublease income Interest income - sales-type sublease - 8,000 Net lease expense $ 21,000 $ 14,000 |
Maturity of Lease Liabilities | Maturity of lease liabilities (as of June 30 2022 Operating lease 2022 $ 23,000 2023 24,000 Total 47,000 Less amount representing interest 2,000 Present value of lease liabilities $ 45,000 Discount rate 5.850 % |
The Southern California Regio_2
The Southern California Regional Gamma Knife Center (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Neuro Partners LLC and CGK [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Equity Method Investment Summarized Financial Information | The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK: NeuroPartners LLC and CGK Condensed Combined Income Statement Information Six Months Ended June 30, 2022 2021 Patient Revenue $ 277,000 $ 336,000 Net (loss) income $ (27,000 ) $ 27,000 USNC’s equity in loss of NeuroPartners, LLC and CGK $ (28,000 ) $ (7,000 ) Three Months Ended June 30, 2022 2021 Patient revenue $ 155,000 $ 170,000 Net income $ 3,000 $ 8,000 USNC’s equity in loss of NeuroPartners LLC and CGK $ (38,000 ) $ (5,000 ) NeuroPartners LLC and CGK Condensed Combined Balance Sheet Information June 30, 2022 December 31, 2021 Current assets $ 370,000 $ 299,000 Noncurrent assets 166,000 294,000 Total assets $ 536,000 $ 593,000 Current liabilities $ 535,000 $ 564,000 Noncurrent liabilities - - Equity 1,000 29,000 Total liabilities and equity $ 536,000 $ 593,000 |
Boca Oncology Partners (Tables)
Boca Oncology Partners (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Equity Method Investment Summarized Financial Information | The following tables present the summarized financial information of BOPRE: BOPRE Condensed Income Statement Information Six Months Ended June 30, 2022 2021 Rental Income $ - $ - Net income $ 31,000 $ 56,000 USNC’s equity in earnings of BOPRE $ 8,000 $ 12,000 Three Months Ended June 30, 2022 2021 Rental Income $ - $ - Net income $ 14,000 $ 38,000 USNC’s equity in earnings of BOPRE $ 4,000 $ 9,000 BOPRE Condensed Balance Sheet Information June 30, 2022 December 31, 2021 Current assets $ 94,000 $ 112,000 Noncurrent assets 757,000 757,000 Total assets $ 851,000 $ 869,000 Current liabilities $ - $ - Noncurrent liabilities - - Equity 851,000 869,000 Total liabilities and equity $ 851,000 $ 869,000 |
Medical Oncology Partners (Tabl
Medical Oncology Partners (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Medical Oncology Partners LLC [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Equity Method Investment Summarized Financial Information | The following table presents the summarized financial information of MOP: MOP Condensed Consolidated Income Statement Information Six Months Ended June 30, 2022 2021 Patient revenue $ 1,067,000 $ 1,068,000 Net loss $ (256,000 ) $ (95,000 ) USNC’s equity in loss in MOP $ (92,000 ) $ (34,000 ) Three Months Ended June 30, 2022 2021 Patient revenue $ 534,000 $ 531,000 Net loss $ (68,000 ) $ 73,000 USNC’s equity in loss of MOP $ (53,000 ) $ 26,000 MOP Condensed Consolidated Balance Sheet Information June 30, 2022 December 31, 2021 Current assets $ 284,000 $ 201,000 Noncurrent assets 241,000 384,000 Total assets $ 525,000 $ 585,000 Current liabilities $ 3,326,000 $ 3,109,000 Noncurrent liabilities 64,000 92,000 Deficit (2,865,000 ) (2,616,000 ) Total liabilities and deficit $ 525,000 $ 585,000 |
CB Oncology Partners (Tables)
CB Oncology Partners (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
CB Oncology Partners LLC [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Equity Method Investment Summarized Financial Information | The following table presents the summarized financial information of CBOP: CBOP Condensed Income Statement Information Six Months Ended June 30, 2022 2021 Patient revenue $ 1,026,000 $ 1,041,000 Net (loss) income $ (237,000 ) $ 92,000 USNC’s equity in (loss) income of CBOP $ (68,000 ) $ 26,000 Three Months Ended June 30, 2022 2021 Patient revenue $ 444,000 $ 570,000 Net (loss) income $ (191,000 ) $ 30,000 USNC’s equity in (loss) income of CBOP $ (55,000 ) $ 8,000 CBOP Condensed Balance Sheet Information June 30, 2022 December 31, 2021 Current assets $ 526,000 $ 400,000 Noncurrent assets 3,362,000 3,667,000 Total assets $ 3,888,000 $ 4,067,000 Current liabilities $ 3,826,000 $ 3,472,000 Noncurrent liabilities 2,826,000 3,121,000 Deficit (2,764,000 ) (2,526,000 ) Total liabilities and deficit $ 3,888,000 $ 4,067,000 |
Restatement of Previously Iss_2
Restatement of Previously Issued Financial Statements (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Restatement of Previously Issued Financial Statements [Abstract] | |
Reconciliation from the Previously Reported to the Restated Values | The restatement tables below present a reconciliation from the previously reported to the restated values as of and for the three and six months ended June 30, 2021. The values as previously reported were derived from the Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 filed on August 11, 2021. CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS For the Three Months Ended June 30, 2021 As previously Restatement Reported Impacts As Restated Income tax provision $ 189,000 $ 43,000 $ 232,000 Net loss $ (574,000 ) $ (43,000 ) $ (617,000 ) Basic and diluted net loss per share $ 0.07 $ (0.01 ) $ (0.08 ) CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS For the Six Months Ended June 30, 2021 Income tax provision $ 194,000 $ 290,000 $ 484,000 Net loss $ (35,000 ) $ (290,000 ) $ (325,000 ) Basic and diluted net loss per share $ (0.00 ) $ (0.04 ) $ (0.04 ) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Six Months Ended June 30, 2021 Net loss $ (35,000 ) $ (290,000 ) $ (325,000 ) Change in: Income taxes receivable/payable $ - $ 369,000 $ 369,000 Deferred income taxes $ 79,000 $ (79,000 ) $ - |
Basis of Preparation (Details)
Basis of Preparation (Details) - USD ($) | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Long-term Assets [Abstract] | |||
Operating lease right-of-use asset | $ 40,000 | $ 77,000 | $ 59,000 |
Total leased assets | 40,000 | 77,000 | |
Current Liabilities [Abstract] | |||
Operating lease right-of-use liability - current portion | 45,000 | 41,000 | 43,000 |
Long-term Liabilities [Abstract] | |||
Operating lease right-of-use liability - net of current portion | 0 | 45,000 | $ 23,000 |
Total lease liabilities | 45,000 | 86,000 | |
Lease Cost [Abstract] | |||
Net lease expense | 21,000 | 14,000 | |
Operating lease [Abstract] | |||
2022 | 23,000 | ||
2023 | 24,000 | ||
Total | 47,000 | ||
Less amount representing interest | 2,000 | ||
Present value of lease liabilities | $ 45,000 | ||
Discount rate | 5.85% | ||
Selling, General and Administrative Expenses [Member] | |||
Lease Cost [Abstract] | |||
Operating lease cost | $ 21,000 | 20,000 | |
Interest Expense [Member] | |||
Lease Cost [Abstract] | |||
Finance lease cost, interest on lease liabilities | 0 | 2,000 | |
Interest Income - Sales-type Sublease [Member] | |||
Lease Cost [Abstract] | |||
Sublease income | $ 0 | $ 8,000 |
Gamma Knife at NYU Medical Ce_2
Gamma Knife at NYU Medical Center (Details) - USD ($) | 6 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2021 | |
Gamma Knives at NYU Medical Center [Abstract] | ||
Cash reserves | $ 1,096,000 | $ 2,178,000 |
NYU [Member] | ||
Gamma Knives at NYU Medical Center [Abstract] | ||
Gain on termination of contract | 100,000 | |
NYU [Member] | Minimum [Member] | ||
Gamma Knives at NYU Medical Center [Abstract] | ||
Cash reserves | $ 1,000,000 |
The Southern California Regio_3
The Southern California Regional Gamma Knife Center (Details) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Apr. 01, 2016 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) Payment | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Feb. 29, 2016 USD ($) | |
The Southern California Regional Gamma Knife Center [Abstract] | |||||||
Renovation installation and operation agreement period | 14 years | ||||||
Lease payment | $ 0 | $ 89,000 | |||||
Due to related parties | $ 47,000 | 47,000 | $ 0 | ||||
Condensed Income Statement Information [Abstract] | |||||||
Patient revenue | 0 | $ 0 | 0 | 1,061,000 | |||
Net (loss) income | (1,291,000) | (617,000) | (1,786,000) | (325,000) | |||
USNC's equity in earnings (loss) | (998,000) | (135,000) | (1,131,000) | (274,000) | |||
Condensed Balance Sheet Information [Abstract] | |||||||
Current assets | 1,153,000 | 1,153,000 | 2,243,000 | ||||
TOTAL ASSETS | 1,659,000 | 1,659,000 | 3,688,000 | ||||
Current liabilities | 406,000 | 406,000 | 626,000 | ||||
Equity | 1,242,000 | 1,242,000 | 3,028,000 | ||||
TOTAL LIABILITIES AND EQUITY | 1,659,000 | 1,659,000 | 3,688,000 | ||||
Neuro Partners LLC and CGK [Member] | |||||||
The Southern California Regional Gamma Knife Center [Abstract] | |||||||
Recorded amount of equity method income (loss) | 0 | (10,000) | |||||
Condensed Income Statement Information [Abstract] | |||||||
Patient revenue | 155,000 | 170,000 | 277,000 | 336,000 | |||
Net (loss) income | 3,000 | 8,000 | (27,000) | 27,000 | |||
Condensed Balance Sheet Information [Abstract] | |||||||
Current assets | 370,000 | 370,000 | 299,000 | ||||
Noncurrent assets | 166,000 | 166,000 | 294,000 | ||||
TOTAL ASSETS | 536,000 | 536,000 | 593,000 | ||||
Current liabilities | 535,000 | 535,000 | 564,000 | ||||
Noncurrent liabilities | 0 | 0 | 0 | ||||
Equity | 1,000 | 1,000 | 29,000 | ||||
TOTAL LIABILITIES AND EQUITY | $ 536,000 | $ 536,000 | 593,000 | ||||
Neuro Partners LLC [Member] | |||||||
The Southern California Regional Gamma Knife Center [Abstract] | |||||||
Ownership percentage | 20% | 20% | |||||
Neuro Partners LLC [Member] | Lease One [Member] | |||||||
The Southern California Regional Gamma Knife Center [Abstract] | |||||||
Share of guarantee in lease obligations | 20% | ||||||
Lease term | 7 years | 7 years | |||||
Lease obligation | $ 668,000 | ||||||
Neuro Partners LLC [Member] | Lease Two [Member] | |||||||
The Southern California Regional Gamma Knife Center [Abstract] | |||||||
Lease term | 5 years | 5 years | |||||
Lease obligation | $ 1,663,000 | ||||||
Number of lease payments | Payment | 60 | ||||||
Lease payment | $ 31,000 | ||||||
CGK [Member] | |||||||
The Southern California Regional Gamma Knife Center [Abstract] | |||||||
Ownership percentage | 39% | 39% | |||||
Due to related parties | $ 47,000 | $ 47,000 | |||||
Due from related parties | $ 6,000 | ||||||
Neuro Partners LLC and CGK [Member] | |||||||
Condensed Income Statement Information [Abstract] | |||||||
USNC's equity in earnings (loss) | $ (38,000) | $ (5,000) | $ (28,000) | $ (7,000) |
Florida Oncology Partners (Deta
Florida Oncology Partners (Details) - USD ($) | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Florida Oncology Partners [Abstract] | |||
Recorded distribution | $ 11,000 | $ 0 | |
Investments in unconsolidated entities | 150,000 | $ 141,000 | |
FOP [Member] | |||
Florida Oncology Partners [Abstract] | |||
Recorded distribution | 0 | ||
Investments in unconsolidated entities | $ 0 | ||
FOP [Member] | USNC [Member] | |||
Florida Oncology Partners [Abstract] | |||
Ownership percentage | 24% |
Boca Oncology Partners (Details
Boca Oncology Partners (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2012 | Jun. 30, 2011 USD ($) | Jun. 30, 2022 USD ($) ft² | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) ft² | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Boca Oncology Partners [Abstract] | |||||||
Recorded investments | $ 150,000 | $ 150,000 | $ 141,000 | ||||
Condensed Income Statement Information [Abstract] | |||||||
Net income | (1,291,000) | $ (617,000) | (1,786,000) | $ (325,000) | |||
USNC's equity in earnings (loss) | (998,000) | (135,000) | (1,131,000) | (274,000) | |||
Condensed Balance Sheet Information [Abstract] | |||||||
Current assets | 1,153,000 | 1,153,000 | 2,243,000 | ||||
TOTAL ASSETS | 1,659,000 | 1,659,000 | 3,688,000 | ||||
Current liabilities | 406,000 | 406,000 | 626,000 | ||||
Equity | 1,242,000 | 1,242,000 | 3,028,000 | ||||
TOTAL LIABILITIES AND EQUITY | 1,659,000 | 1,659,000 | 3,688,000 | ||||
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | |||||||
Condensed Income Statement Information [Abstract] | |||||||
Rental income | 0 | 0 | 0 | 0 | |||
Net income | 14,000 | 38,000 | 31,000 | 56,000 | |||
Condensed Balance Sheet Information [Abstract] | |||||||
Current assets | 94,000 | 94,000 | 112,000 | ||||
Noncurrent assets | 757,000 | 757,000 | 757,000 | ||||
TOTAL ASSETS | 851,000 | 851,000 | 869,000 | ||||
Current liabilities | 0 | 0 | 0 | ||||
Noncurrent liabilities | 0 | 0 | 0 | ||||
Equity | 851,000 | 851,000 | 869,000 | ||||
TOTAL LIABILITIES AND EQUITY | $ 851,000 | $ 851,000 | $ 869,000 | ||||
Boca Oncology Partners, LLC [Member] | |||||||
Boca Oncology Partners [Abstract] | |||||||
Area of real estate property (in square foot) | ft² | 6,000 | 6,000 | |||||
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | |||||||
Boca Oncology Partners [Abstract] | |||||||
Ownership percentage | 24.36% | 24.36% | 24.36% | ||||
Recorded investments | $ 150,000 | $ 150,000 | $ 151,000 | ||||
Condensed Income Statement Information [Abstract] | |||||||
USNC's equity in earnings (loss) | $ 4,000 | $ 9,000 | $ 8,000 | $ 12,000 | |||
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | Boca West IMP [Member] | |||||||
Boca Oncology Partners [Abstract] | |||||||
Percentage of interest in medical office building | 20% | ||||||
Ownership percentage | 23.75% | ||||||
Additional investor purchased ownership percentage | 3.75% | ||||||
BOP and BOPRE [Member] | |||||||
Boca Oncology Partners [Abstract] | |||||||
Area of real estate property (in square foot) | ft² | 32,000 | 32,000 | |||||
Investments in unconsolidated entities | $ 225,000 | ||||||
Ownership percentage | 22.50% |
Medical Oncology Partners (Deta
Medical Oncology Partners (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||||
Dec. 31, 2016 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 23, 2016 | |
Medical Oncology Partners [Abstract] | |||||||
Carrying value of investment | $ 150,000 | $ 150,000 | $ 141,000 | ||||
Advances to unconsolidated entities | 175,000 | $ 288,000 | |||||
Condensed Consolidated Income Statement Information [Abstract] | |||||||
Patient revenue | 0 | $ 0 | 0 | 1,061,000 | |||
Net loss | (1,291,000) | (617,000) | (1,786,000) | (325,000) | |||
USNC's equity in (loss) income | (998,000) | (135,000) | (1,131,000) | (274,000) | |||
Condensed Consolidated Balance Sheet Information [Abstract] | |||||||
Current assets | 1,153,000 | 1,153,000 | 2,243,000 | ||||
TOTAL ASSETS | 1,659,000 | 1,659,000 | 3,688,000 | ||||
Current liabilities | 406,000 | 406,000 | 626,000 | ||||
Deficit | 1,242,000 | 1,242,000 | 3,028,000 | ||||
TOTAL LIABILITIES AND EQUITY | 1,659,000 | 1,659,000 | 3,688,000 | ||||
MOP [Member] | |||||||
Condensed Consolidated Income Statement Information [Abstract] | |||||||
Patient revenue | 534,000 | 531,000 | 1,067,000 | 1,068,000 | |||
Net loss | (68,000) | 73,000 | (256,000) | (95,000) | |||
Condensed Consolidated Balance Sheet Information [Abstract] | |||||||
Current assets | 284,000 | 284,000 | 201,000 | ||||
Noncurrent assets | 241,000 | 241,000 | 384,000 | ||||
TOTAL ASSETS | 525,000 | 525,000 | 585,000 | ||||
Current liabilities | 3,326,000 | 3,326,000 | 3,109,000 | ||||
Noncurrent liabilities | 64,000 | 64,000 | 92,000 | ||||
Deficit | (2,865,000) | (2,865,000) | (2,616,000) | ||||
TOTAL LIABILITIES AND EQUITY | 525,000 | $ 525,000 | $ 585,000 | ||||
MOP [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Equity interest percentage to be acquired by subsidiary | 100% | ||||||
Investments in unconsolidated entities | $ 450,000 | ||||||
Advances to unconsolidated entities | 189,000 | 277,000 | |||||
Condensed Consolidated Income Statement Information [Abstract] | |||||||
USNC's equity in (loss) income | $ (12,000) | (53,000) | $ 26,000 | (92,000) | $ (34,000) | ||
MOP [Member] | Other Investor [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Investments in unconsolidated entities | 105,000 | ||||||
MOP [Member] | USNC [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Investments in unconsolidated entities | 173,000 | ||||||
Ownership percentage | 35.83% | ||||||
Carrying value of investment | $ 149,000 | 149,000 | $ 161,000 | ||||
MOP [Member] | USNC [Member] | Dr. Jaime Lozano [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Investments in unconsolidated entities | $ 345,000 | ||||||
Ownership percentage | 76.67% | 76.67% | |||||
Percentage of equity interest to an additional investor as a consulting fee for services | 5% |
CB Oncology Partners (Details)
CB Oncology Partners (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2020 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Sep. 02, 2017 | |
Condensed Income Statement Information [Abstract] | |||||||
Patient revenue | $ 0 | $ 0 | $ 0 | $ 1,061,000 | |||
Net (loss) income | (1,291,000) | (617,000) | (1,786,000) | (325,000) | |||
USNC's equity in (loss) income | (998,000) | (135,000) | (1,131,000) | (274,000) | |||
Condensed Balance Sheet Information [Abstract] | |||||||
Current assets | 1,153,000 | 1,153,000 | $ 2,243,000 | ||||
TOTAL ASSETS | 1,659,000 | 1,659,000 | 3,688,000 | ||||
Current liabilities | 406,000 | 406,000 | 626,000 | ||||
Deficit | 1,242,000 | 1,242,000 | 3,028,000 | ||||
TOTAL LIABILITIES AND EQUITY | 1,659,000 | 1,659,000 | 3,688,000 | ||||
CB Oncology Partners LLC [Member] | |||||||
Condensed Income Statement Information [Abstract] | |||||||
Patient revenue | 444,000 | 570,000 | 1,026,000 | 1,041,000 | |||
Net (loss) income | (191,000) | 30,000 | (237,000) | 92,000 | |||
Condensed Balance Sheet Information [Abstract] | |||||||
Current assets | 526,000 | 526,000 | 400,000 | ||||
Noncurrent assets | 3,362,000 | 3,362,000 | 3,667,000 | ||||
TOTAL ASSETS | 3,888,000 | 3,888,000 | 4,067,000 | ||||
Current liabilities | 3,826,000 | 3,826,000 | 3,472,000 | ||||
Noncurrent liabilities | 2,826,000 | 2,826,000 | 3,121,000 | ||||
Deficit | (2,764,000) | (2,764,000) | (2,526,000) | ||||
TOTAL LIABILITIES AND EQUITY | 3,888,000 | 3,888,000 | 4,067,000 | ||||
CB Oncology Partners LLC [Member] | |||||||
CB Oncology Partners [Abstract] | |||||||
Ownership percentage | 28.58% | 24% | |||||
Capital called from members | $ 500,000 | ||||||
Advances converted into equity | 121,000 | ||||||
Contribution in cash | $ 212,000 | ||||||
Outstanding amount | $ 2,211,000 | $ 2,211,000 | |||||
Note bearing interest | 6% | 6% | |||||
Accrued interest | $ 427,000 | $ 427,000 | $ 335,000 | ||||
Condensed Income Statement Information [Abstract] | |||||||
USNC's equity in (loss) income | $ (55,000) | $ 8,000 | $ (68,000) | $ 26,000 |
Elite Health (Details)
Elite Health (Details) | Oct. 01, 2021 |
Elite Health Plan, Inc. [Member] | |
Elite Health [Abstract] | |
Equity consideration, percentage of outstanding shares | 15% |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Income Taxes [Abstract] | ||||
Federal and state income taxes, rate | 0% | 304% | ||
Tax provision | $ 1,000 | $ 232,000 | $ 3,000 | $ 484,000 |
Restatement of Previously Iss_3
Restatement of Previously Issued Financial Statements, Condensed Consolidated Statements of Operations (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] | ||||
Income tax provision | $ 1,000 | $ 232,000 | $ 3,000 | $ 484,000 |
Net loss | $ (1,291,000) | $ (617,000) | $ (1,786,000) | $ (325,000) |
Basic net loss per share (in dollars per share) | $ (0.14) | $ (0.08) | $ (0.19) | $ (0.04) |
Diluted net loss per share (in dollars per share) | $ (0.14) | $ (0.08) | $ (0.19) | $ (0.04) |
As Previously Reported [Member] | ||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] | ||||
Income tax provision | $ 189,000 | $ 194,000 | ||
Net loss | $ (574,000) | $ (35,000) | ||
Basic net loss per share (in dollars per share) | $ 0.07 | $ 0 | ||
Diluted net loss per share (in dollars per share) | $ 0.07 | $ 0 | ||
Restatement Impacts [Member] | ||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] | ||||
Income tax provision | $ 43,000 | $ 290,000 | ||
Net loss | $ (43,000) | $ (290,000) | ||
Basic net loss per share (in dollars per share) | $ (0.01) | $ (0.04) | ||
Diluted net loss per share (in dollars per share) | $ (0.01) | $ (0.04) |
Restatement of Previously Iss_4
Restatement of Previously Issued Financial Statements, Condensed Consolidated Statements of Cash Flows (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] | ||||
Net loss | $ (1,291,000) | $ (617,000) | $ (1,786,000) | $ (325,000) |
Change in: Income taxes receivable/payable | $ (183,000) | 369,000 | ||
Deferred income taxes | 0 | |||
As Previously Reported [Member] | ||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] | ||||
Net loss | (574,000) | (35,000) | ||
Change in: Income taxes receivable/payable | 0 | |||
Deferred income taxes | 79,000 | |||
Restatement Impacts [Member] | ||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] | ||||
Net loss | $ (43,000) | (290,000) | ||
Change in: Income taxes receivable/payable | 369,000 | |||
Deferred income taxes | $ (79,000) |